undamentalytics Newsletter

Wong Roderick: insider trades

Chief executive, Director, 10% owner at 6 companies we cover. 21 open-market purchases and 2 sales not made under a pre-set plan, reported from October 2, 2019 to May 1, 2025.

Would copying Wong Roderick’s purchases have beaten the S&P 500?

Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on October 3, 2019 into $37,180 by November 2, 2026, +20.4% a year. The copy held shares only 39% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $19,490, +9.9% a year (the S&P 500 held throughout made $28,788, +16.2% a year). Beta against the index was 0.49. Twelve months after each report, the average purchase was +197.3% against the S&P 500 (median +316.4%), and 80% beat it: within what luck alone would produce (p = 0.88 over 4 years). Measured from the trade date, the insider’s own timing, the average was +206.1%. After their sales, the shares moved −32.5% against the index over 12 months on average (a negative figure means selling was the right call); 50% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$25.0k$50.0k$75.0k 20192020202120222023202420252026 $37.2k$28.8k$19.5k
Copying Wong RoderickS&P 500, same days investedS&P 500, held throughout $10,000 copying Wong Roderick’s open-market purchases from October 3, 2019, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+20.4%
S&P 500, same days invested
+9.9% (held throughout +16.2%)
Time in shares
39%
Sharpe ratio (S&P 500)
0.55 (0.71)
Biggest drop (S&P 500)
−80% (−34%)
Market sensitivity (beta)
0.49
Purchases copied
20

Trade by trade

Wong Roderick: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 20 +24.9% +40.5% 75% 4 −0.01 0.99 No reliable evidence
Purchases, 6 months after the report 20 +65.4% +93.0% 75% 4 −0.36 0.74 No reliable evidence
Purchases, 12 months after the report 20 +197.3% +316.4% 80% 4 0.17 0.88 No reliable evidence
Purchases, 12 months after the trade 20 +206.1% +332.1% 80% 4 0.26 0.81 No reliable evidence
Sales, 3 months after the report 2 −28.4% −28.4% 100% 2 — — Not enough years
Sales, 12 months after the report 2 −32.5% −32.5% 50% 2 — — Not enough years
Sales, 12 months after the trade 2 −24.7% −24.7% 50% 2 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Immunovant, Inc. IMVT Chief Executive Officer120November 12, 2019December 13, 2019
Stoke Therapeutics, Inc. STOK —30October 2, 2019November 6, 2019
Orchestra Biomed Holdings, Inc. OBIO Chief Executive Officer30July 25, 2022May 1, 2025
Milestone Pharmaceuticals Inc. MIST —20October 15, 2019January 13, 2020
Tela Bio, Inc. TELA —11December 17, 2019December 18, 2019
Rocket Pharmaceuticals, Inc. RCKT —01May 13, 2021May 13, 2021

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 1, 2025April 30, 2025 OBIO Purchase $149,201 not yetnot yetnot yet
January 26, 2023January 24, 2023 OBIO Purchase $18,085,120 +37.1%−56.1%−45.3%
July 25, 2022July 22, 2022 OBIO Purchase $10,010,000 +2.0%−57.3%−48.4%
May 13, 2021May 11, 2021 RCKT Sale $29,021,750 −34.3%−75.5%−75.7%
January 13, 2020January 13, 2020 MIST Purchase $4,387,500 −71.3%−79.1%−77.3%
December 18, 2019December 17, 2019 TELA Sale $407,520 −22.5%+10.4%+26.2%
December 17, 2019December 13, 2019 TELA Purchase $277,240 −20.0%+21.4%+22.7%
December 13, 2019December 11, 2019 IMVT Purchase $343,980 −13.8%+251.8%+313.9%
December 10, 2019December 10, 2019 IMVT Purchase $269,579 +47.2%+313.9%+318.8%
December 9, 2019December 6, 2019 IMVT Purchase $4,100,000 +47.8%+318.8%+359.4%
December 9, 2019December 6, 2019 IMVT Purchase $510,000 +47.8%+318.8%+359.4%
December 5, 2019December 5, 2019 IMVT Purchase $203,000 +56.5%+359.4%+357.5%
December 4, 2019December 4, 2019 IMVT Purchase $203,000 +70.0%+357.5%+375.3%
December 3, 2019November 29, 2019 IMVT Purchase $693,493 +63.1%+375.3%+353.3%
November 29, 2019November 25, 2019 IMVT Purchase $125,880 +63.8%+361.6%+345.4%
November 22, 2019November 20, 2019 IMVT Purchase $489,075 +49.7%+345.4%+351.1%
November 19, 2019November 15, 2019 IMVT Purchase $744,772 +39.0%+351.1%+397.5%
November 14, 2019November 12, 2019 IMVT Purchase $1,281,420 +52.0%+397.5%+365.4%
November 12, 2019November 7, 2019 IMVT Purchase $310,490 +42.1%+366.7%+370.1%
November 6, 2019November 4, 2019 STOK Purchase $3,066,487 +12.1%+25.7%+18.6%
November 1, 2019October 30, 2019 STOK Purchase $1,966,717 −16.7%+18.6%+26.6%
October 15, 2019October 10, 2019 MIST Purchase $95,462 −13.0%−81.0%−76.7%
October 2, 2019October 1, 2019 STOK Purchase $693,058 +2.9%+36.6%+35.4%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Wong Roderick traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.